Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 April 2021 | Story André Damons | Photo André Damons
Hannes Erasmus, an assistant bioanalyst in the Division of Immunochemistry at FARMOVS, a wholly owned clinical research company of the University of the Free State (UFS), will be graduating on Friday with a Master of Science degree majoring in Human Molecular Genetics.

While working on his study for his MSc Human Genetics degree, a staff member of FARMOVS – who was a Gamete intrafallopian tube (GIFT) baby – not only got to meet the doctor who was responsible for his being, but the doctor also formed part of his supervisor team.

Hannes Erasmus, an assistant bioanalyst in the Division of Immunochemistry at FARMOVS, a wholly owned clinical research company of the University of the Free State (UFS), will be graduating on Thursday (22 April 2021) with a Master of Science degree majoring in Human Molecular Genetics. His dissertation is titled Genetic and Molecular Analysis of Male infertility in a private practice in South Africa. His supervisor team consisted of Mrs Sue-Rica Schneiders (supervisor), Dr Gerda Marx, Dr Olga de Smidt, and Prof PH (Paul) Wessels (co-supervisors).

“I feel very proud and fortunate to have the opportunity to complete this achievement. It was not easy, but it gave me more time during lockdown to write up my thesis. One of my biggest challenges was time itself. Late nights in the lab and writing up at night,” says Erasmus about studying and working during the year of COVID-19.

GIFT baby

According to Erasmus, he decided on this topic because he had an interest in infertility from an early age, since he was also a GIFT baby. 

“My parents struggled for a while to conceive after my older sister was born.  They decided on this assisted reproductive technique, and I was conceived. I then had the privilege to meet the doctor who was responsible for my being, Prof Wessels.  He then also formed part of my supervisor team and allowed me to sample my case group at his private fertility clinic.”

His wife, Bernadine, inspires him to be a better version of himself each day.  He strives to contribute to his workspace, his friends, family, and community to grow and better the future of South Africa and our children.

Dean’s Medal 
A colleague of Erasmus – Vicky Simpson, Marketing Manager of FARMOVS, is the recipient of the Dean’s Medal for achieving the best results in respect of a Bachelor Honours degree in the Faculty of Economic and Management Sciences at the UFS. 

Simpson, who graduated with a Bachelor of Commerce Honours with specialisation in Marketing during the virtual graduation on Monday, says she is shocked and at first did not notice that she was the recipient of this award. She obtained her degree with distinction.

“I will always be grateful! Not everyone gets the opportunity to study at a university. Yes, I had to work twice as hard to achieve my goals, but I think I craved success enough to overcome all the challenges.”

                            Vicky Simpson, Marketing Manager of FARMOVS,Picture: André Damons


Grabbed the opportunity with both hands

“I never had the opportunity to study before the age of 30. My family had very limited financial resources.  As a result, my main focus was day-to-day survival. So, I had to find creative ways to make this dream happen. When the doors of opportunity opened here at the UFS, I grabbed it with both hands and made the best of numerous challenging situations. It meant that I had to study and perform well at work, because both aspects deserved my full attention. In the end, I don’t regret the sacrifices I made. I also hope that I made those who believed in my potential very proud,” says Simpson.

“I will always remain grateful to Prof Jonathan Jansen, former Rector and Vice-Chancellor of the UFS, and his wife Grace. They gave me a valuable opportunity back in 2014, which transformed my life. My colleague Pat Lamusse also played a significant role in my development, because she believed in me when it mattered the most.” 

According to Simpson, it was difficult to stay motivated and focused (during COVID-19) while the world was in a state of turmoil and uncertainty.  It required more energy than it would have under normal circumstances. 

“Luckily, my partner Cornél, my friends, colleagues, and family were there to offer me support. I felt like quitting a few times, but grit and vision pushed me forward towards my goal. My amazing study leader, Prof Jacques Nel, was just so inspiring and helpful. We made a stellar team, and my dissertation remains the best document that I have ever submitted. The weekends and late nights spent on writing that document was worth it!”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept